Compounds > 3',4',5',3,4,5-hexamethoxy-chalcone
Page last updated: 2024-12-11

3',4',5',3,4,5-hexamethoxy-chalcone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID6145900
CHEMBL ID17442
MeSH IDM0487618

Synonyms (14)

Synonym
nsc-96356
nsc96356
(e)-1,3-bis(3,4,5-trimethoxyphenyl)prop-2-en-1-one
2-propen-1-one, 1,3-bis(3,4,5-trimethoxyphenyl)-, (2e)-
3,3',4,4',5,5'-hexamethoxychalcone
CHEMBL17442
(2e)-1,3-bis(3,4,5-trimethoxyphenyl)prop-2-en-1-one
AKOS022023317
STL433604
3',4',5',3,4,5-hexamethoxy-chalcone
130768-87-5
unii-ryu875g50o
1,3-bis(3,4,5-trimethoxyphenyl)prop-2-en-1-one, (e)-
ryu875g50o ,
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (27)

Assay IDTitleYearJournalArticle
AID247832Antiproliferative activity against human Colon cancer HT-29 cell line; Not Tested2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
Synthesis and biological evaluation of chalcones and their derived pyrazoles as potential cytotoxic agents.
AID54717Inhibition of COX-2 activity in intact human monocytes1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
Synthesis and anti-inflammatory activity of chalcone derivatives.
AID247738Antiproliferative activity against human cancer DU-145 cell line; Not Tested2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
Synthesis and biological evaluation of chalcones and their derived pyrazoles as potential cytotoxic agents.
AID134716In vivo inhibition of compound required to inhibit LTB4 levels in zymosan treated mouse air pouch at a dose of 100 nmol/pouch1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
Synthesis and anti-inflammatory activity of chalcone derivatives.
AID247758Antiproliferative activity against prostate cancer PC-3 cell line; Not Tested2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
Synthesis and biological evaluation of chalcones and their derived pyrazoles as potential cytotoxic agents.
AID247572Antiproliferative activity against human cancer OVCAR-5 cell line2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
Synthesis and biological evaluation of chalcones and their derived pyrazoles as potential cytotoxic agents.
AID744718Cytotoxicity against mouse L1210 cells after 24 hrs by MTT assay2013European journal of medicinal chemistry, May, Volume: 63Cytotoxic 3,4,5-trimethoxychalcones as mitotic arresters and cell migration inhibitors.
AID134718In vivo inhibition of compound required to inhibit TNF-alpha levels in zymosan treated mouse air pouch at a dose of 100 nmol/pouch1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
Synthesis and anti-inflammatory activity of chalcone derivatives.
AID453129Inhibition of nitric oxide production in LPS/IFN-gamma-stimulated BALB/c mouse peritoneal macrophages by Griess method2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Synthesis and biological evaluation of 3',4',5'-trimethoxychalcone analogues as inhibitors of nitric oxide production and tumor cell proliferation.
AID247740Antiproliferative activity against human cancer SNB-78 cell line; Not Tested2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
Synthesis and biological evaluation of chalcones and their derived pyrazoles as potential cytotoxic agents.
AID6749Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
Synthesis and anti-inflammatory activity of chalcone derivatives.
AID247628Antiproliferative activity against human colon cancer HCT-15 cell line2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
Synthesis and biological evaluation of chalcones and their derived pyrazoles as potential cytotoxic agents.
AID453127Growth inhibition of human HepG2 cells after 48 hrs by MTT assay2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Synthesis and biological evaluation of 3',4',5'-trimethoxychalcone analogues as inhibitors of nitric oxide production and tumor cell proliferation.
AID247851Antiproliferative activity against human colon cancer SW-620 cell line; Not Tested2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
Synthesis and biological evaluation of chalcones and their derived pyrazoles as potential cytotoxic agents.
AID134717In vivo inhibition of compound required to inhibit PGE-2 levels in zymosan treated mouse air pouch at a dose of 100 nmol/pouch1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
Synthesis and anti-inflammatory activity of chalcone derivatives.
AID91336Inhibitory concentration required for LTB4 synthesis in stimulated human neutrophils1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
Synthesis and anti-inflammatory activity of chalcone derivatives.
AID515791Inhibition of telomerase in human A549 cells at 25 uM after 24 hrs by TRAP assay2010Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19
Identification of small molecule inhibitors of telomerase activity through transcriptional regulation of hTERT and calcium induction pathway in human lung adenocarcinoma A549 cells.
AID91337Percent inhibition required for elastase release in stimulated human neutrophils1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
Synthesis and anti-inflammatory activity of chalcone derivatives.
AID453128Growth inhibition of human COLO205 cells after 48 hrs by MTT assay2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Synthesis and biological evaluation of 3',4',5'-trimethoxychalcone analogues as inhibitors of nitric oxide production and tumor cell proliferation.
AID247739Antiproliferative activity against human cancer SKOV-3 cell line; Not Tested2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
Synthesis and biological evaluation of chalcones and their derived pyrazoles as potential cytotoxic agents.
AID247513Antiproliferative activity against human SIHA cell line2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
Synthesis and biological evaluation of chalcones and their derived pyrazoles as potential cytotoxic agents.
AID502775Antibacterial activity against Helicobacter pylori ATCC 700392 at 0.5 ug/ml by disk agar diffusion method2010Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18
Identification of 3',4',5'-trimethoxychalcone analogues as potent inhibitors of Helicobacter pylori-induced inflammation in human gastric epithelial cells.
AID452430Antiproliferative activity against human K562 cells after 5 days by MTT assay2009Bioorganic & medicinal chemistry, Nov-15, Volume: 17, Issue:22
Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: synthesis and biological evaluation of antivascular activity.
AID247554Antiproliferative activity against human cancer A-549 cell line2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
Synthesis and biological evaluation of chalcones and their derived pyrazoles as potential cytotoxic agents.
AID247564Antiproliferative activity against human cancer HOP-62 cell line2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
Synthesis and biological evaluation of chalcones and their derived pyrazoles as potential cytotoxic agents.
AID134715In vivo inhibition of compound required for migration of neutrophils into the mouse pouch at the dose of 100 nmol/pouch1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
Synthesis and anti-inflammatory activity of chalcone derivatives.
AID247555Antiproliferative activity against human cancer Hep-2 cell line2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
Synthesis and biological evaluation of chalcones and their derived pyrazoles as potential cytotoxic agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (12.50)18.2507
2000's4 (50.00)29.6817
2010's3 (37.50)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.80

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.80 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index5.00 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.80)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
metronidazole
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.		2.0510C-nitro compound;
imidazoles;
primary alcohol		antiamoebic agent;
antibacterial drug;
antimicrobial agent;
antiparasitic agent;
antitrichomonal drug;
environmental contaminant;
prodrug;
radiosensitizing agent;
xenobiotic
n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide: structure given in first source. NS-398 : A C-nitro compound that is N-methylsulfonyl-4-nitroaniline bearing an additional cyclohexyloxy substituent at position 2.		1.9910aromatic ether;
C-nitro compound;
sulfonamide		antineoplastic agent;
cyclooxygenase 2 inhibitor
colchicine
(S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.		2.0810alkaloid;
colchicine		anti-inflammatory agent;
gout suppressant;
mutagen
amoxicillin
Amoxicillin: A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration.. amoxicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-(4-hydroxyphenyl)acetamido group.		2.0510penicillin allergen;
penicillin		antibacterial drug
3,5-dihydroxy-4-methoxybenzoic acid
3,5-dihydroxy-4-methoxybenzoic acid: catechol methyltransferase inhibitor; N1 same as NM		2.0510trihydroxybenzoic acid
clarithromycin
Clarithromycin: A semisynthetic macrolide antibiotic derived from ERYTHROMYCIN that is active against a variety of microorganisms. It can inhibit PROTEIN SYNTHESIS in BACTERIA by reversibly binding to the 50S ribosomal subunits. This inhibits the translocation of aminoacyl transfer-RNA and prevents peptide chain elongation.. clarithromycin : The 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis.		2.0510macrolide antibioticantibacterial drug;
environmental contaminant;
protein synthesis inhibitor;
xenobiotic
methotrexate
[no description available]		2.0510dicarboxylic acid;
monocarboxylic acid amide;
pteridines		abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent
zm 230487
ZM 230487: a 5-lipoxygenase inhibitor		1.9910
chalcone
trans-chalcone : The trans-isomer of chalcone.		2.7430chalconeEC 3.2.1.1 (alpha-amylase) inhibitor
bilirubin
[no description available]		2.0210biladienes;
dicarboxylic acid		antioxidant;
human metabolite;
mouse metabolite
fosbretabulin
[no description available]		2.0510stilbenoid
lespenefril
lespenefril: RN given refers to (L)-isomer. kaempferol 3,7-di-O-alpha-L-rhamnoside : A glycosyloxyflavone that is kaempferol attached to alpha-L-rhamnopyranosyl residues at positions 3 and 7 respectively via glycosidic linkages. It has been isolated from the aerial parts of Vicia faba and Lotus edulis.		2.0510alpha-L-rhamnoside;
dihydroxyflavone;
glycosyloxyflavone;
monosaccharide derivative;
polyphenol		anti-inflammatory agent;
antidepressant;
antineoplastic agent;
apoptosis inducer;
bone density conservation agent;
hypoglycemic agent;
immunomodulator;
plant metabolite
metochalcone
metochalcone: structure		2.0510
mdl 27048
MDL 27048: structure given in first source; powerful & reversible microtubule inhibitor		2.0510
combretastatin a-4 disodium phosphate
[no description available]		2.0510
3-hydroxy-4,3',4',5'-tetramethoxychalcone
3-hydroxy-4,3',4',5'-tetramethoxychalcone: structure in first source		2.7430
3,4-methylenedioxy-3',4',5'-trimethoxy chalcone
[no description available]		2.4420
o-acetyl-adp-ribose
O-Acetyl-ADP-Ribose: An acetyl ester of ADENOSINE DIPHOSPHATE RIBOSE formed during NAD-dependent deacetylation of proteins by SIRTUINS. The acetate group resides on the ribose ring where nicotinamide was cleaved from NAD during the reaction. Several isomers of O-acetyl-ADP-ribose have been isolated from the reaction.. 2''-O-acetyl-ADP-D-ribose : A nucleotide-sugar having ADP as the nucleotide fragment and 2-O-acetyl-D-ribofuranos-5-yl as the sugar component.		2.0210nucleotide-sugar
ConditionIndicatedRelationship StrengthStudiesTrials
Benign Neoplasms
[description not available]		02.0210
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.0210
Infections, Helicobacter
[description not available]		02.0510
Gastritis
Inflammation of the GASTRIC MUCOSA, a lesion observed in a number of unrelated disorders.		02.0510
Helicobacter Infections
Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.		02.0510
Adenocarcinoma, Basal Cell
[description not available]		02.0510
Cancer of Lung
[description not available]		02.0510
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		02.0510
Lung Neoplasms
Tumors or cancer of the LUNG.		02.0510